<DOC>
	<DOC>NCT00113165</DOC>
	<brief_summary>This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.</brief_summary>
	<brief_title>Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of epilepsy with partial seizures for more than 24 weeks. Must experience at least 8 partial seizures during an 8week Baseline Phase. Must currently be receiving treatment with a stable regimen of one or two antiepileptic drugs for at least four weeks. Patient or parent/caregiver must be willing and able to maintain a written daily seizure diary. Exclusion criteria: Previous treatment with lamotrigine. Exhibits any primary generalized seizures. Receiving treatment with felbamate or currently following the ketogenic diet. Pregnant, breastfeeding, or planning to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>partial seizures</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>antiepileptic drugs</keyword>
	<keyword>anticonvulsants</keyword>
	<keyword>LAMICTAL</keyword>
	<keyword>seizures</keyword>
	<keyword>lamotrigine</keyword>
</DOC>